NCT04740021

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Taizhou HoudeAoke Biomedical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

LP002 is a highly selected recombinant humanized anti-PD-L1 monoclonal antibody. This is a single-arm, multicenter study to evaluate the efficacy and safety of LP002 in combination with chemotherapy in patients with extensive stage samll cell lung cancer.

Conditions

• Small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	LP002	10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
DRUG	Carboplatin	AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.
DRUG	Etoposide	100 mg/m\^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.

Timeline

• Start date: 2020-12-02
• Primary completion: 2022-02-01
• Completion: 2022-08-01
• First posted: 2021-02-05
• Last updated: 2021-02-05

Locations

8 sites across 1 country: China